In recent months, three new appointments have expanded the Optellum team to grow commercial adoption of the Optellum Virtual Nodule Clinic software in the USA. Ryan Hennen (VP of US Sales)…
Business Insider highlights Optellum amongst top healthcare start-ups that are heating up and set to take off in 2021. Business Insider interviewed dozens of venture capitalists and other private investors to learn which…
Dr Vachani presented a virtual poster as a three-minute video as part of a session that highlighted lung cancer projects across the continuum of care.
Optellum is proud to be a key industry partner in a £11M University of Oxford-led AI programme to accelerate lung cancer diagnosis. NHS England and three industry leaders, Optellum, Roche,…
Global leading doctors from Vanderbilt and Oxford have published independent clinical validation of the Optellum Lung Cancer Prediction AI, illustrating its potential to shorten time to diagnosis. The paper, with…
The Optellum artificial intelligence prediction model has been demonstrated to outperform the best currently used model. Prediction of the likelihood of malignancy is central to the clinical management of suspicious…
Optellum has strengthened leadership team to support the commercialisation and clinical validation of its first product, and the development of product pipeline in the treatment of lung cancer and other…
Optellum Chairman & co-founder, Prof. Sir Michael Brady FRS (center), is named the founding Board of Trustees member, and the interim President of the world's first AI University. Prof Sir…
Optellum Founder and Chief Science & Technology Officer will share the lessons learned by Optellum in enabling early lung cancer diagnosis & treatment at the AI@Oxford congress. University of Oxford…
IASLC World Conference on Lung Cancer, the world's premier event for physicians and scientists advancing the fight against world's deadliest cancer, is taking place from September 7th till September 10…
The Optellum team is excited to be selected for the 2019 Digital Health Accelerator Cohort at TMCx, to be spend 4 months building our business with industry and clinical experts…
Optellum team and advisors took the lead role in preparing the winning bid, with Optellum Chairman, Prof Sir Michael Brady FRS named the Executive Chairman of the NCIMI consortium led…